TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Recommendation of “Buy” by Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned a consensus rating of “Buy” from the nine ratings firms that are covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $11.79.

Several equities research analysts have recently commented on the company. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price for the company. Roth Mkm started coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 price target on the stock. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Canaccord Genuity Group reduced their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th.

TriSalus Life Sciences Stock Up 2.3 %

Shares of TLSI stock opened at $4.80 on Thursday. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42. The firm has a market cap of $146.37 million, a PE ratio of -1.93 and a beta of 0.51. The stock has a 50 day moving average of $4.39 and a 200-day moving average of $4.78.

Insider Buying and Selling

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius acquired 62,972 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the purchase, the insider now directly owns 6,230,748 shares of the company’s stock, valued at $24,736,069.56. The trade was a 1.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders bought 70,012 shares of company stock valued at $281,235. Company insiders own 32.80% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

Several large investors have recently added to or reduced their stakes in TLSI. Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at $66,000. Virtu Financial LLC acquired a new position in TriSalus Life Sciences in the 3rd quarter valued at $92,000. Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences in the third quarter valued at approximately $108,000. MSD Partners L.P. purchased a new position in TriSalus Life Sciences in the third quarter valued at about $184,000. Finally, Geode Capital Management LLC boosted its position in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares in the last quarter. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.